Who owns C4 Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of CCCC from SEC Form 13F filings across 147 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 147 institutions disclosed 117.6M shares of C4 Therapeutics, Inc. worth $547.6M — about 90% of shares outstanding; the largest disclosed holder is MORGAN STANLEY. Source: SEC Form 13F filings, parsed by EvidInvest.
147
13F holders
$547.6M
value, 2026 filers
90%
of shares outstanding (117.6M sh)
51
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of CCCC's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 8.9M | $41.4M | 0.0% | 6.8% | -2.3% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 8.0M | $37.4M | 0.3% | 6.1% | 0.0% |
| 3 | BlackRock, Inc. | 7.9M | $36.9M | 0.0% | 6% | +285.5% |
| 4 | Lynx1 Capital Management LP | 7.3M | $34.2M | 4.0% | 5.6% | +4.7% |
| 5 | Squadron Capital Management LLC | 7.2M | $33.6M | 10.4% | 5.5% | +220.0% |
| 6 | Bain Capital Life Sciences Investors, LLC | 7.2M | $33.5M | 2.0% | 5.5% | 0.0% |
| 7 | JPMORGAN CHASE & CO | 4.7M | $20.7M | 0.0% | 3.6% | +47.3% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 4.4M | $20.6M | 0.0% | 3.4% | +14.4% |
| 9 | CITADEL ADVISORS LLC | 4.2M | $19.6M | 0.0% | 3.2% | +66.8% |
| 10 | GOLDMAN SACHS GROUP INC | 3.5M | $16.5M | 0.0% | 2.7% | +47.9% |
| 11 | WASATCH ADVISORS LP | 3.5M | $16.5M | 0.1% | 2.7% | +18.9% |
| 12 | TWO SIGMA INVESTMENTS, LP | 3.5M | $16.2M | 0.0% | 2.7% | +14.3% |
| 13 | Soleus Capital Management, L.P. | 3.4M | $15.8M | 0.5% | 2.6% | -11.2% |
| 14 | SILVERARC CAPITAL MANAGEMENT, LLC | 3.0M | $14.2M | 1.5% | 2.3% | +58.6% |
| 15 | BANK OF AMERICA CORP /DE/ | 2.7M | $12.4M | 0.0% | 2% | +12.6% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 2.5M | $11.8M | 0.0% | 1.9% | +165.2% |
| 17 | Ikarian Capital, LLCNEW | 2.4M | $11.4M | 1.2% | 1.9% | new |
| 18 | STATE STREET CORP | 2.1M | $9.9M | 0.0% | 1.6% | +452.4% |
| 19 | ACADIAN ASSET MANAGEMENT LLC | 1.8M | $8.4M | 0.0% | 1.4% | -4.5% |
| 20 | Candriam S.C.A.NEW | 1.8M | $8.4M | 0.0% | 1.4% | new |
| 21 | D. E. Shaw & Co., Inc. | 1.7M | $8.1M | 0.0% | 1.3% | +64.2% |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.7M | $8.1M | 0.0% | 1.3% | +34.6% |
| 23 | Patient Square Capital LPNEW | 1.6M | $7.5M | 1.2% | 1.2% | new |
| 24 | HighVista Strategies LLCNEW | 1.3M | $6.3M | 1.4% | 1% | new |
| 25 | RENAISSANCE TECHNOLOGIES LLC | 1.2M | $5.6M | 0.0% | 0.9% | -51.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.